FDA moves ahead with safety study of abortion pill mifepristone
The FDA is advancing a large safety study of mifepristone. The review could influence future limits on telehealth, mail delivery, and who can prescribe it.
Intelligence analysis by GPT-5.4 Mini
The FDA is moving forward with a retrospective safety review of mifepristone, the abortion pill used for early pregnancies. The study could shape whether the Trump administration seeks tighter access rules, even as officials say the review has been underway for months.
The FDA is looking closely at a medicine used to end very early pregnancies, checking lots of past cases like a librarian reviewing many books. If the review leads to stricter rules, getting the medicine could become harder, especially by mail or online.
Analysis
What the FDA is doing
A senior FDA official told CBS News the agency is moving ahead with a retrospective safety study of mifepristone based on hundreds of thousands of cases. The official said interim results could be available in July, while the timing of final results depends on a later secondary analysis.
Why this is politically sensitive
The review sits inside a larger fight over abortion access. Administration officials say the study has been underway for months, not newly launched, and the FDA said it has been conducting a science-based review of the drug. But the timing has drawn scrutiny from some congressional Republicans and anti-abortion groups, who have argued the agency may have been moving too slowly.
The legal backdrop
The drug came under renewed pressure after the Biden administration eased restrictions that had required in-person dispensing and allowed access through telehealth and mail. Louisiana later sued over the mailing rule. On May 4, the 5th U.S. Circuit Court of Appeals temporarily restored an in-person dispensing requirement, but the Supreme Court set that order aside the following week, so mail delivery remains allowed for now while the case continues.
What could change
Mifepristone was first approved in 2000 and is usually taken with misoprostol. CBS medical correspondent Dr. Celine Gounder said withdrawing approval would be difficult and likely invite legal challenges. A more realistic effect, based on the reporting, would be narrower access: fewer options for telehealth or mail delivery, or tighter prescribing rules that limit which clinicians can provide it.
Key points
- The FDA is advancing a retrospective safety study of mifepristone covering hundreds of thousands of cases.
- Interim results could be released in July, but the final timeline is still uncertain.
- The review could become a path to tighter access rules, especially for telehealth and mail delivery.
- The issue is tied to ongoing legal fights, including Louisiana's lawsuit and a Supreme Court order preserving mail access for now.
- Experts quoted in the story say a full withdrawal of approval would be difficult and would likely trigger legal challenges.
If the review confirms the drug’s safety, it could reinforce current access through telehealth and mail. That would preserve a major option for patients and clinicians while the courts keep working through the Louisiana case.
If the review is used to justify tighter rules, access could become harder even without a full ban. The article says that could mean limits on mail delivery, telehealth, or who is allowed to prescribe the drug.
